News

AccurKardia announced a multi-year agreement with Lucem Health, a leading provider of clinical AI solutions. The partnership paves the way for AccurKardia to integrate its FDA-Cleared ECG Interpretation Software Platform, AccurECG™ Analysis System, into Lucem Health Reveal, a family of solutions that identify patients who may be at higher risk of severe or chronic diseases.

AccurKardia announced today that its flagship product, the AccurECG™ Analysis System (“AccurECG” or the “System”), has been granted FDA 510(k) clearance. AccurECG™ is a cloud-based, device-agnostic and fully automated electrocardiogram (ECG) interpretation software platform.

AccurKardia announced our final closing and completion of our $2.7 million Series Seed round. This funding milestone marks a significant step towards AccurKardia’s goal of improving patients’ outcomes and saving millions of lives regardless of geography.

AccurKardia announced today it will collaborate with Mawi, to integrate its proprietary ECG analytics into Mawi’s new cardiac monitoring watch. This collaboration highlights AccurKardia’s commitment to enabling world-class cardiac-care through remote patient monitoring solutions.

AccurKardia’s AccurBeat has been found to be a promising new alternative for QT/QTc remote monitoring according to a new study published on JMIR Publications and conducted by HITLAB and SUNY Downstate College of Medicine.

The AccurKardia team is excited to join the Innovators’ Network. We are eager to engage with the other network members and the Center, as we pursue our goal of delivering ECG analytics solutions that improve patient outcomes.

Our Co-Founder and CEO, Juan C. Jimenez recently authored an article published by Nasdaq on Telehealth 2.0, discussing how remote patient monitoring tools can give a ‘shot in the arm’ to the virtual care revolution.

In this interview AccurKardia's CEO describes how the Company is improving patients' outcomes and saving lives.

AccurKardia today announced a collaboration with MDF Instruments to develop ECG (electrocardiogram) solutions for the next generation of stethoscopes. This collaboration brings together AccurKardia’s cutting edge innovation in device-agnostic, automated ECG analytics with clinical-grade accuracy and MDF Instruments’ more than 40 years of experience designing, manufacturing, and distributing premium diagnostic instruments.

This article showcases 62 top picks for the best New York City based Health Diagnostics companies. AccurKardia was identified as a cutting edge startup that is taking a variety of approaches to innovating the Health Diagnostics industry.

Life Science Intelligence's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.The AccurKardia platform will be device agnostic and will support automated detection and diagnosis for ambulatory, in-patient telemetry, and consumer ECG devices. As the prevalence of arrhythmia increases in proportion with the growing elderly population, easy-to-use solutions for the detection and diagnostic will become an essential tool to slow the progression of this chronic condition.

This article showcases The Startup Pill’s top picks for the best Health Diagnostics startups. Accurkardia was included as one of the 101 companies or start up for its contribution to the healthcare space around the world. AccurKardia was mentioned as an exceptional startups well worth a follow.